MELANOMA

This blog is a collection of my favorite new treatments for melanoma currently available through clinical trials. The start of each post contains a brief description of the approach, reasons I included it and a link to the trial website.

Validation of Vemurafenib in Previously Treated BRAF V600 – Mutated Metastatic Melanoma: BRIM 2 Update

Vemurafenib (PLX4032) is a next generation oral BRAF inhibitor for the treatment of metastatic melanoma harbouring the BRAF V600 mutation. Update from the BRIM 2 trial on previously treated patients has shown that 53% of the patients experienced… [Learn More…]

Vemurafenib (PLX4032) for Metastatic Melanoma

PLX4032 is a next generation oral BRAF inhibitor for the treatment of melanoma. Data from the BRIM 2 clinical trial of previously untreated melanoma patients showed that  53% of the patients experienced tumor shrinkage compared with only 5% for… [Learn More…]

Using Patient Derived Tumor Infiltrating Lymphocytes To Treat Metastatic Melanoma

Tumor infiltrating lymphocytes (TIL) are white blood cells that are taken from a patients tumor tissue, expanded and primed (activated) against known melanoma proteins, and injected back into the patient. In an ongoing trial, 50–75% of the… [Learn More…]